Search Results - Kentsch, Angela

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Abstract PD10-11: Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype

    Abstract PD10-11: Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with tra... by Kuemmel, Sherko, Gluz, Oleg, Reinisch, Mattea, Kostara, Athina, Scheffen, Iris, Graeser, Monika, Wuerstlein, Rachel, Nitz, Ulrike, Luedtke-Heckenkamp, Kerstin, Hartkopf, Andreas, Hilpert, Felix, Kentsch, Angela, Ziske, Carsten, Depenbusch, Reinhard, Braun, Michael, Blohmer, Jens, zu Eulenburg, Christine, Christgen, Matthias, Bartels, Stephan, Kreipe, Hans, Pelz, Enrico, Schmid, Peter, Harbeck, Nadia

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Abstract P2-13-03: KEYRICHED-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype

    Abstract P2-13-03: KEYRICHED-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with t... by Kuemmel, Sherko, Gluz, Oleg, Reinisch, Mattea, Kostara, Athina, Scheffen, Iris, Graeser, Monika, Luedtke-Heckenkamp, Kerstin, Hartkopf, Andreas, Hilpert, Felix, Kentsch, Angela, Ziske, Carsten, Depenbusch, Reinhard, Braun, Michael, Blohmer, Jens, zu Eulenburg, Christine, Christgen, Matthias, Bartels, Stephan, Kreipe, Hans, Pelz, Enrico, Schmid, Peter, Harbeck, Nadia

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Abstract P5-02-03: Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial

    Abstract P5-02-03: Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched ea... by Graeser, Monika, Kuemmel, Sherko, Gluz, Oleg, Feuerhake, Friedrich, Volk, Valery, Ulbrich-Gebauer, Daniel, Biehl, Claudia, Reinisch, Mattea, Kostara9, Athina, Scheffen, Iris, Luedtke-Heckenkamp, Kerstin, Hartkopf, Andreas, Hilpert, Felix, Kentsch, Angela, Ziske, Carsten, Depenbusch, Reinhard, Braun, Michael, Blohmer, Jens-Uwe, zu Eulenburg, Christine, Christgen, Matthias, Kates, Ronald, Bartels, Stephan, Kreipe, Hans-Heinrich, Pelz, Enrico, Schmid, Peter, Harbeck, Nadia

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: